Champions Oncology Beheer
Beheer criteriumcontroles 4/4
Champions Oncology's CEO is Ronnie Morris, appointed in Jan 2017, has a tenure of 7.83 years. total yearly compensation is $400.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 6.32% of the company’s shares, worth $3.44M. The average tenure of the management team and the board of directors is 3.2 years and 13.4 years respectively.
Belangrijke informatie
Ronnie Morris
Algemeen directeur
US$400.0k
Totale compensatie
| Percentage CEO-salaris | 100.0% |
| Dienstverband CEO | 7.8yrs |
| Eigendom CEO | 6.3% |
| Management gemiddelde ambtstermijn | 3.2yrs |
| Gemiddelde ambtstermijn bestuur | 13.4yrs |
Recente managementupdates
Recent updates
Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth
Oct 24
It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)
Jun 14Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?
Sep 28Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Jul 21We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
Oct 14We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth
Jun 21Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?
Apr 09Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Mar 19The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?
Mar 02Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?
Feb 04Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?
Jan 14Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares
Dec 19Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results
Dec 16
Champions Oncology beats on revenue
Dec 14Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 04Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | -US$3m |
| Apr 30 2024 | US$400k | US$400k | -US$7m |
| Jan 31 2024 | n/a | n/a | -US$10m |
| Oct 31 2023 | n/a | n/a | -US$10m |
| Jul 31 2023 | n/a | n/a | -US$8m |
| Apr 30 2023 | US$600k | US$400k | -US$5m |
| Jan 31 2023 | n/a | n/a | -US$3m |
| Oct 31 2022 | n/a | n/a | US$108k |
| Jul 31 2022 | n/a | n/a | US$401k |
| Apr 30 2022 | US$800k | US$400k | US$548k |
| Jan 31 2022 | n/a | n/a | US$219k |
| Oct 31 2021 | n/a | n/a | US$391k |
| Jul 31 2021 | n/a | n/a | US$115k |
| Apr 30 2021 | US$775k | US$375k | US$362k |
| Jan 31 2021 | n/a | n/a | -US$1m |
| Oct 31 2020 | n/a | n/a | -US$2m |
| Jul 31 2020 | n/a | n/a | -US$1m |
| Apr 30 2020 | US$1m | US$394k | -US$2m |
| Jan 31 2020 | n/a | n/a | -US$181k |
| Oct 31 2019 | n/a | n/a | -US$956k |
| Jul 31 2019 | n/a | n/a | -US$995k |
| Apr 30 2019 | US$146k | US$146k | US$128k |
| Jan 31 2019 | n/a | n/a | -US$251k |
| Oct 31 2018 | n/a | n/a | US$42k |
| Jul 31 2018 | n/a | n/a | -US$320k |
| Apr 30 2018 | US$244k | n/a | -US$1m |
Compensatie versus markt: Ronnie's total compensation ($USD400.00K) is below average for companies of similar size in the US market ($USD655.02K).
Compensatie versus inkomsten: Ronnie's compensation has been consistent with company performance over the past year.
CEO
Ronnie Morris (58 yo)
7.8yrs
Tenure
US$400,000
Compensatie
Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017. Dr. Morris previously served as the President and a Director of Champions Oncology, Inc. from Oc...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 7.8yrs | US$400.00k | 6.32% $ 3.4m | |
| Chief Financial Officer | 7.5yrs | US$260.00k | 0.041% $ 22.1k | |
| Chief Operating Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Vice President of Technology | 4.5yrs | geen gegevens | geen gegevens | |
| Vice President of Global Marketing | no data | geen gegevens | geen gegevens | |
| Executive Vice President of Global Laboratory Operations | 3.2yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | no data | geen gegevens | geen gegevens | |
| Executive Vice President of Global Scientific Operations | 3.2yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Commercial | 1.3yrs | geen gegevens | geen gegevens |
3.2yrs
Gemiddelde duur
Ervaren management: CSBR's management team is considered experienced (3.2 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 14.1yrs | US$400.00k | 6.32% $ 3.4m | |
| Independent Director | 13.4yrs | US$93.30k | 0.22% $ 120.0k | |
| Independent Chairman of the Board | 14.1yrs | US$116.62k | 7.08% $ 3.8m | |
| Independent Lead Director | 17.3yrs | US$85.54k | 5.64% $ 3.1m | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Independent Director | 11.7yrs | US$85.52k | 1.46% $ 794.5k | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Independent Director | 8.6yrs | US$85.54k | 0.11% $ 58.6k | |
| Board Observer | no data | geen gegevens | geen gegevens | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Independent Director | 3.8yrs | US$82.20k | 0% $ 0 |
13.4yrs
Gemiddelde duur
58.5yo
Gemiddelde leeftijd
Ervaren bestuur: CSBR's board of directors are seasoned and experienced ( 13.4 years average tenure).